Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase NA 4Phase 1 4Phase 1/2 2Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia 5Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphohistiocytosis, Hemophagocytic 2Leukemia, Myelomonocytic, Juvenile 2Hodgkin Disease 2Shwachman-Diamond Syndrome 1Primary Immunodeficiency Diseases 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Oropharyngeal Neoplasms 1Neutropenia, Severe Congenital, Autosomal Recessive 3 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Macrophage Activation Syndrome 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Histiocytosis, Langerhans-Cell 1Histiocytosis 1Hemoglobinopathies 1Cranial Nerve Diseases 1

Interventions

Cyclophosphamide 18fludarabine phosphate 16Rituximab 16Etoposide 16Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14fludarabine 11Whole-Body Irradiation 11Nivolumab 11Mycophenolic Acid 11Bendamustine Hydrochloride 11Tacrolimus 10Melphalan 10Filgrastim 9Gemcitabine 8Carboplatin 8Ifosfamide 7Cytarabine 7Cyclosporine 7Busulfan 7pembrolizumab 6Lenalidomide 6Doxorubicin 6Prednisone 5Everolimus 5Antilymphocyte Serum 5Alemtuzumab 5Vinblastine 4Methotrexate 4Mesna 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Hodgkin Disease × Methylprednisolone × Clear all
NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

NCT02243436 2019-04-24

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 1/2 Completed
67 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡